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QUALITY ASSESSMENT OF META-ANALYSES OF
RCTS OF PHARMACOTHERAPY IN MAJOR
DEPRESSIVE DISORDER
Hemels MEH,Vicente C, Sadri H, Masson MJ, Einarson TR
University of Toronto,Toronto, ON, Canada
OBJECTIVES: Meta-analyses (MAs) of randomized con-
trolled trials (RCTs) are considered to provide the highest
level of evidence. There has been a substantial increase in
the number of published MAs, but of unknown quality.
Therefore, we determined the quality of reporting in MAs
of RCTs of pharmacotherapy used in the treatment 
of major depressive disorder (MDD) in adults (18–65)
without comorbidities. We also examined trends over
time. METHODS: MEDLINE, EMBASE, Healthstar,
Psychlit and Cochrane databases were searched from
1980–2002 by 4 independent reviewers for MAs of RCTs
reporting efﬁcacy rates. Articles meeting inclusion crite-
ria were blinded. Interrater reliability (Kappa) and test-
retest between 4 raters was evaluated using 4 articles. MA
quality was assessed using the QUORUM checklist com-
prising 6 sections (Title, Abstract, Introduction, Methods,
Results, Discussion) with 18 questions in total, each
awarded 1 point. Descriptive statistics were used to cal-
culate overall MA quality. Time trends were evaluated by
calculating Spearman’s rho. RESULTS: Fifty-nine articles
were identiﬁed, 26 were excluded (comorbidities (12),
inappropriate compartor (7), no RCT (1), article not
available (6)); 33 were included. Initial kappa was 0.81
(p < 0.05). After resolution of disagreements through con-
sensus, the test-retest reliability was signiﬁcant (kappa =
0.89; p < 0.05). The average overall quality score was
50.3% (SD = 15.6%, range = 16.7%–88.9%, median =
50.0%). The overall score for Titles was very poor (21%),
Abstracts (39%) and Methods (49%) had poor scores,
while the overall Results score was minimally acceptable
(55%). Good quality scores were found for the Intro-
duction (91%) and Discussion (100%). No time trends
were identiﬁed (rho = 0.08; p = 0.68). CONCLUSIONS:
Although quality guidelines have been published, the
average quality of published MAs of antidepressants is
barely acceptable (50.3%). There is a need for adherence
to standardized reporting and quality guidelines.
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A META-ANALYSIS AND COMMON
COMPARATOR ANALYSIS OF OLANZAPINE
VERSUS ZIPRASIDONE AND ARIPIPRAZOLE
Davey PJ1, Mudge MAC1, Croker VS2,Aldridge G1,
FitzGerald P1
1Medical Technology Assessment Group, Chatswood West,
NSW, Australia; 2Eli Lilly Australia Pty Ltd, West Ryde,
Australia
OBJECTIVE: This meta-analysis aimed to compare the
relative clinical beneﬁt of olanzapine, a widely used ﬁrst-
line drug for the treatment of schizophrenia, with two
newer atypical antipsychotics, ziprasidone and aripipra-
zole, using an indirect common comparator approach.
METHODS: No comparative trials had been completed
of olanzapine versus ziprasidone or aripiprazole at 
the time of the analysis, and so a common comparator
approach via haloperidol, a benchmark typical antipsy-
chotic, was employed. This method formally compares
the absolute risk difference for the various atypicals com-
pared with the common reference drug, haloperidol. All
double-blind, randomised, controlled trials of olanzapine,
ziprasidone or aripiprazole versus haloperidol were
included in the meta-analysis. Random-effects and ﬁxed-
effects methods were employed and standard tests were
used to determine heterogeneity. Studies were separated
by duration into short-term trials (12 weeks or less) and
medium- to long-term trials (>12 weeks). RESULTS: The
results of the medium- to longer-term comparison of 
olanzapine with ziprasidone showed that a signiﬁcantly
smaller proportion of patients treated with olanzapine
required anticholinergics medication (p = 0.019) and
fewer olanzapine-treated patients discontinued treat-
ment due to any reason (p = 0.034), compared with those
receiving ziprasidone. The short-term comparison of
olanzapine with aripiprazole showed that signiﬁcantly
fewer olanzapine-treated patients required anticholinergic
medication, compared with the aripiprazole-treated
patients (p = 0.006). In the longer-term, a statistically sig-
niﬁcant difference in proportion of responders was
revealed, favouring olanzapine (p = 0.024). CONCLU-
SIONS: This analysis suggests that olanzapine is safer, as
measured by less anticholinergic use, and is associated
with fewer dropouts than ziprasidone in the medium- to
longer-term. It is also suggested that olanzapine is safer,
as measured by less anticholinergic use, than aripiprazole
in the short-term and more efﬁcacious in the longer-term.
Despite a lack of head-to-head trials, the common com-
parator analysis allows indicative judgments to be made
about the relative safety and efﬁcacy of new therapies.
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THE TREATMENT CHARACTERISTICS AND
OUTCOMES OF PERSONS WITH DEPRESSION
AND ALCOHOLISM
Mark TL
The MEDSTAT Group, Inc, Washington, DC, USA
OBJECTIVE: To examine the type of treatment being
provided to patients with depression and alcoholism and
the outcomes from treatment as compared to patients
with depression alone. METHODS: Paid claims data
from large employers offering private insurance were ana-
lyzed for the period 1997–2000. Persons were identiﬁed
as having depression and alcoholism if they had a diag-
nosis of depression and either an alcoholism diagnosis, an
alcoholism medication, or alcoholism detoxiﬁcation or
